Form 4 for OVID Ovid Therapeutics Inc.
Accepted 2024-02-26 00:00:00 ET · period of report 2024-02-22 · accession 0001209191-24-003966 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-02-26 | 2024-02-22 | OVID | Perone Thomas Michael | GC, Sec | A - Grant | $0.00 | +28.1K | 28.1K | New | $0 |
| D | 2024-02-26 | 2024-02-22 | OVID | Perone Thomas Michael | GC, Sec | A - Grant | $0.00 | +168.8K | 168.8K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-22 | A | A | 28,125 | $0.00 | 28,125 | D | — | — | (F1) Represents a restricted stock unit (RSU) award. One-third (1/3) of the total number of RSUs shall vest on January 1, 2025 and one-third (1/3) of the remaining RSUs shall vest each year thereafter on anniversary of the vesting commencement date, subject to the Reporting Person's continuous service through such vesting date. (F2) Each RSU represents a contingent right to receive one share of Common Stock. |
| 2 | Derivative | Stock Option (Right to Buy) | 2024-02-22 | A | A | 168,750 | $0.00 | 168,750 | D | $3.68 · — to 2034-02-21 | 168,750 Common Stock | (F3) 25% of the shares subject to the Stock Option will vest and become exercisable on February 22, 2025 and the remaining shares will vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued services through such date. |